AAAAAA

   
Results: 1-9 |
Results: 9
PROSPECTIVE ECONOMIC-EVALUATION OF PHASE-III TRIAL COMPARING IRINOTECAN WITH INFUSIONAL 5-FU IN PATIENTS WITH ADVANCED COLORECTAL-CANCER
Authors: SCHMITT C JOLAIN B VANCUTSEM E
Citation: C. Schmitt et al., PROSPECTIVE ECONOMIC-EVALUATION OF PHASE-III TRIAL COMPARING IRINOTECAN WITH INFUSIONAL 5-FU IN PATIENTS WITH ADVANCED COLORECTAL-CANCER, Medical decision making, 18(4), 1998, pp. 484-484
THE CANADIAN STUDY OF CARDIAC TRANSPLANTATION ATHEROSCLEROSIS
Authors: CARRIER M RIVARD M KOSTUK W LATTER D JOLAIN B DALY P DAVIES R TEO K GUDAS V SULLIVAN J
Citation: M. Carrier et al., THE CANADIAN STUDY OF CARDIAC TRANSPLANTATION ATHEROSCLEROSIS, Circulation, 98(17), 1998, pp. 2874-2874
COST-EFFECTIVENESS OF IRINOTECAN (CPT-11) AND BEST ESTIMATED CHEMOTHERAPY REGIMEN IN PATIENTS WITH METASTATIC COLORECTAL-CANCER AFTER FAILURE OF 5FLUOROURACIL (5FU) CONTAINING REGIMEN - RESULTS BASED ON A PHASE-III TRIAL
Authors: BLIJHAM G SCHMITT C AUSSAGE P HENRYLAUNOIS B JOLAIN B HERAIT P
Citation: G. Blijham et al., COST-EFFECTIVENESS OF IRINOTECAN (CPT-11) AND BEST ESTIMATED CHEMOTHERAPY REGIMEN IN PATIENTS WITH METASTATIC COLORECTAL-CANCER AFTER FAILURE OF 5FLUOROURACIL (5FU) CONTAINING REGIMEN - RESULTS BASED ON A PHASE-III TRIAL, European journal of cancer, 33, 1997, pp. 4-4
A MODEL OF PATIENTS PREFERENCES FOR CHEMOTHERAPY OUTCOMES IN ADVANCEDCOLORECTAL-CANCER - DO GAINS IN SURVIVAL JUSTIFY THE TOXICITY
Authors: SCHMITT C HENRYLAUNOIS B JOLAIN B CAVALLO MC MANTOVANI L
Citation: C. Schmitt et al., A MODEL OF PATIENTS PREFERENCES FOR CHEMOTHERAPY OUTCOMES IN ADVANCEDCOLORECTAL-CANCER - DO GAINS IN SURVIVAL JUSTIFY THE TOXICITY, European journal of cancer, 33, 1997, pp. 56-56
A PROSPECTIVE COMPARISON OF 4 STUDY DESIGNS USED IN ASSESSING SAFETY AND EFFECTIVENESS OF DRUG-THERAPY IN HYPERTENSION MANAGEMENT
Authors: LEVINE MAH HAMET P NOVOSEL S JOLAIN B
Citation: Mah. Levine et al., A PROSPECTIVE COMPARISON OF 4 STUDY DESIGNS USED IN ASSESSING SAFETY AND EFFECTIVENESS OF DRUG-THERAPY IN HYPERTENSION MANAGEMENT, American journal of hypertension, 10(11), 1997, pp. 1191-1200
HEART-TRANSPLANTATION IN CANADA AND DETERMINANTS OF EARLY AND LATE MORTALITY
Authors: DAVIES RA RIVARD M PFLUGFELDER PW JOLAIN B
Citation: Ra. Davies et al., HEART-TRANSPLANTATION IN CANADA AND DETERMINANTS OF EARLY AND LATE MORTALITY, Journal of the American College of Cardiology, 29(2), 1997, pp. 10178-10178
IS PACLITAXEL AND CISPLATIN A COST-EFFECTIVE FIRST-LINE THERAPY FOR ADVANCED OVARIAN-CARCINOMA
Authors: COVENS A BOUCHER S ROCHE K MACDONALD M PETTITT D JOLAIN B SOUETRE E RIVIERE M
Citation: A. Covens et al., IS PACLITAXEL AND CISPLATIN A COST-EFFECTIVE FIRST-LINE THERAPY FOR ADVANCED OVARIAN-CARCINOMA, Cancer, 77(10), 1996, pp. 2086-2091
COST-EFFECTIVENESS ANALYSIS OF LIPID-MODIFYING THERAPY IN CANADA - COMPARISON OF HMG-COA REDUCTASE INHIBITORS IN THE PRIMARY PREVENTION OF CORONARY HEART-DISEASE
Authors: JOLAIN B PETTITT D
Citation: B. Jolain et D. Pettitt, COST-EFFECTIVENESS ANALYSIS OF LIPID-MODIFYING THERAPY IN CANADA - COMPARISON OF HMG-COA REDUCTASE INHIBITORS IN THE PRIMARY PREVENTION OF CORONARY HEART-DISEASE, Clinical therapeutics, 17(3), 1995, pp. 572-575
RCT OF POSTMARKETING SURVEILLANCE METHODS
Authors: LEVINE MAH HAMET P NOVOSEL S JOLAIN B
Citation: Mah. Levine et al., RCT OF POSTMARKETING SURVEILLANCE METHODS, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 147-147
Risultati: 1-9 |